99 related articles for article (PubMed ID: 34247767)
1. Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.
Gadducci A; Multinu F; Cosio S; Carinelli S; Ghioni M; Aletti GD
Gynecol Oncol; 2021 Sep; 162(3):741-750. PubMed ID: 34247767
[TBL] [Abstract][Full Text] [Related]
2. Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.
Okamoto A; Glasspool RM; Mabuchi S; Matsumura N; Nomura H; Itamochi H; Takano M; Takano T; Susumu N; Aoki D; Konishi I; Covens A; Ledermann J; Mezzanzanica D; Steer C; Millan D; McNeish IA; Pfisterer J; Kang S; Gladieff L; Bryce J; Oza A
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S20-5. PubMed ID: 25341576
[TBL] [Abstract][Full Text] [Related]
3. Comparison of surgical and oncologic outcomes in patients with clear cell ovarian carcinoma associated with and without endometriosis.
Charatsingha R; Hanamornroongruang S; Benjapibal M; Therasakvichya S; Jaishuen A; Chaopotong P; Srichaikul P; Jareemit N
Arch Gynecol Obstet; 2021 Dec; 304(6):1569-1576. PubMed ID: 34023979
[TBL] [Abstract][Full Text] [Related]
4. Clear cell carcinoma of the ovary: Clues for radiologists to perform a correct diagnosis.
Rodrigues S; Braga M; Félix A; Cunha TM
Curr Probl Diagn Radiol; 2024; 53(2):271-279. PubMed ID: 37925237
[TBL] [Abstract][Full Text] [Related]
5. From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer.
Liu Z; Jing C; Kong F
J Ovarian Res; 2024 Feb; 17(1):39. PubMed ID: 38347608
[TBL] [Abstract][Full Text] [Related]
6. Specific issues in the systemic treatment strategy for ovarian clear cell carcinoma.
Kfoury M; Tan D
ESMO Open; 2024 Apr; 9(4):102568. PubMed ID: 38387110
[No Abstract] [Full Text] [Related]
7. Establishment of a human ovarian clear cell carcinoma cell line mutant in PIK3CB but not PIK3CA.
Hoshino H; Inoue D; Shinagawa A; Yoshida H; Shigeto S; Matsuda K; Akama TO; Yoshida Y; Kobayashi M
Hum Cell; 2024 Apr; ():. PubMed ID: 38573494
[TBL] [Abstract][Full Text] [Related]
8. Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer.
Fujiwara S
Jpn J Clin Oncol; 2023 Jul; 53(8):664-672. PubMed ID: 37288485
[TBL] [Abstract][Full Text] [Related]
9. New therapies for clear cell ovarian carcinoma.
Stewart J; Cunningham N; Banerjee S
Int J Gynecol Cancer; 2023 Mar; 33(3):385-393. PubMed ID: 36878571
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Assessment and Prognostic Associations of the Immune Landscape in Ovarian Clear Cell Carcinoma.
Khalique S; Nash S; Mansfield D; Wampfler J; Attygale A; Vroobel K; Kemp H; Buus R; Cottom H; Roxanis I; Jones T; von Loga K; Begum D; Guppy N; Ramagiri P; Fenwick K; Matthews N; Hubank MJF; Lord CJ; Haider S; Melcher A; Banerjee S; Natrajan R
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359755
[TBL] [Abstract][Full Text] [Related]
11. Ovarian Clear Cell Carcinoma: Genomic Characterization, Pathogenesis and Targeted Therapy.
Xie Y; Kong W; Luo D; Chen S; Zhao X; Zhang HE
Anticancer Res; 2023 Aug; 43(8):3401-3410. PubMed ID: 37500149
[TBL] [Abstract][Full Text] [Related]
12. ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.
Kuroda Y; Chiyoda T; Kawaida M; Nakamura K; Aimono E; Yoshimura T; Takahashi M; Saotome K; Yoshihama T; Iwasa N; Sakai K; Yamagami W; Nishihara H; Aoki D
Gynecol Oncol; 2021 Sep; 162(3):679-685. PubMed ID: 34272091
[TBL] [Abstract][Full Text] [Related]
13. NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
Armstrong DK; Alvarez RD; Backes FJ; Bakkum-Gamez JN; Barroilhet L; Behbakht K; Berchuck A; Chen LM; Chitiyo VC; Cristea M; DeRosa M; Eisenhauer EL; Gershenson DM; Gray HJ; Grisham R; Hakam A; Jain A; Karam A; Konecny GE; Leath CA; Leiserowitz G; Liu J; Martin L; Matei D; McHale M; McLean K; Miller DS; Percac-Lima S; Remmenga SW; Schorge J; Stewart D; Thaker PH; Vargas R; Hendrickson AW; Werner TL; Zsiros E; Dwyer MA; Hang L
J Natl Compr Canc Netw; 2022 Sep; 20(9):972-980. PubMed ID: 36075393
[TBL] [Abstract][Full Text] [Related]
14. A clearer view on ovarian clear cell carcinoma.
De Pauw A; Naert E; Van de Vijver K; Philippe T; Vandecasteele K; Denys H
Acta Clin Belg; 2022 Aug; 77(4):792-804. PubMed ID: 34404331
[TBL] [Abstract][Full Text] [Related]
15. Mixed squamous and clear cell ovarian adenocarcinoma arising from endometriosis in a 71 year old patient.
Mills A; Saleh M; Erdem Kombak F; Flint M; Kolev V
Gynecol Oncol Rep; 2023 Aug; 48():101225. PubMed ID: 37415960
[TBL] [Abstract][Full Text] [Related]
16. H2Bub1 loss is an early contributor to clear cell ovarian cancer progression.
Ferrari AJ; Rawat P; Rendulich HS; Annapragada AV; Kinose Y; Zhang X; Devins K; Budina A; Scharpf RB; Mitchell MA; Tanyi JL; Morgan MA; Schwartz LE; Soong TR; Velculescu VE; Drapkin R
JCI Insight; 2023 Jun; 8(12):. PubMed ID: 37345659
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy.
McNamara B; Bellone S; Demirkiran C; Max Philipp Hartwich T; Santin AD
Gynecol Oncol Rep; 2023 Aug; 48():101218. PubMed ID: 37325296
[TBL] [Abstract][Full Text] [Related]
18. Ovarian clear cell carcinoma with or without endometriosis origin in a single institution cohort.
Sun M; Jiang W
Discov Oncol; 2023 Apr; 14(1):39. PubMed ID: 37004660
[TBL] [Abstract][Full Text] [Related]
19. Review the progression of ovarian clear cell carcinoma from the perspective of genomics and epigenomics.
Tong A; Di X; Zhao X; Liang X
Front Genet; 2023; 14():952379. PubMed ID: 36873929
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
